Health
LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint – News-Medical.Net
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by…
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results…
-
Noosa News21 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
Noosa News19 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
Noosa News22 hours agoMan dead after breaking into childcare centre
-
Business20 hours agoInvested in IAG shares? Here are the key dates for FY26